|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
muscarinic receptor agonist
|
|
gptkbp:analyzes
|
gptkb:Dr._Jane_Doe
gptkb:Dr._John_Smith
|
|
gptkbp:class
|
piperidine derivatives
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:USA
high
Phase II
Phase I
|
|
gptkbp:collaborations
|
gptkb:Research_Institute
|
|
gptkbp:combatants
|
high affinity for M1 receptors
low affinity for M3 receptors
moderate affinity for M2 receptors
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_performance
|
stable under normal conditions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0761
|
|
gptkbp:indication
|
gptkb:psychologist
schizophrenia
|
|
gptkbp:ingredients
|
C20 H24 N2 O2
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not marketed yet
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:receives_funding_from
|
gptkb:Company
|
|
gptkbp:regulatory_compliance
|
not yet approved
|
|
gptkbp:related_to
|
cognitive enhancement
|
|
gptkbp:research
|
ongoing studies
promising results
|
|
gptkbp:research_areas
|
gptkb:University_of_California
neurology
treatment of cognitive disorders
|
|
gptkbp:research_focus
|
neuropharmacology
|
|
gptkbp:safety_features
|
generally safe
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
rare allergic reactions
|
|
gptkbp:social_structure
|
non-linear
|
|
gptkbp:status
|
under investigation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target_audience
|
adults
elderly
|
|
gptkbp:targets
|
muscarinic acetylcholine receptors
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
324.42 g/mol
|
|
gptkbp:year_created
|
gptkb:2010
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|